⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 23, 2019The Lancet Infectious DiseasesOpen Access

Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study

View Full Paper

Ask AI

Bookmark

Share

Abstract

Bill & Melinda Gates Foundation, Research Foundation-Flanders, and the Belgian-American Education Foundation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bilcke et al. (2019) studied this question.

synapsesocial.com/papers/69d6c080fca0359822aa833a https://doi.org/10.1016/s1473-3099(18)30804-1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Original Research · 2016 · 7,241 citations
2Updated estimates of typhoid fever burden in sub-Saharan AfricaOriginal Research · 2017 · 64 citations
3The burden of typhoid fever in low- and middle-income countries: A meta-regression approachOriginal Research · 2017 · 334 citations
4Emergence of an Extensively Drug-Resistant <i>Salmonella enterica</i> Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation CephalosporinsOriginal Research · 2018 · 642 citations
5Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 StudyRCT · 2015 · 206 citations